You are here

Pfizer

Pfizer, BioNTech start study testing next COVID-19 vaccine

Pfizer, BioNTech start study testing next COVID-19 vaccine

BioPharma Dive

clinical trials

Flag link:

Pfizer musters J&J, PhRMA's support in closely watched Vyndaqel copay assistance case at Supreme Court

Pfizer musters J&J, PhRMA's support in closely watched Vyndaqel copay assistance case at Supreme Court

Fierce Pharma

copay asssistance programs

Flag link:

Best Places to Work in Biopharma 2023 Report Reveals Most Sought-After Employers

Best Places to Work in Biopharma 2023 Report Reveals Most Sought-After Employers

BioSpace

corporate culture

Moderna Therapeutics

Flag link:

Pfizer faces labor action in Australia as workers protest wage increase at manufacturing facility

Pfizer faces labor action in Australia as workers protest wage increase at manufacturing facility

Endpoints

drug manufacturing

Flag link:

Biohaven fuels up for post-Pfizer future with $302M fundraising, fresh faces in the C-suite

Biohaven fuels up for post-Pfizer future with $302M fundraising, fresh faces in the C-suite

Fierce Biotech

Flag link:

Moderna’s Spikevax has higher risk of heart inflammation than Pfizer’s Comirnaty: Study

Moderna’s Spikevax has higher risk of heart inflammation than Pfizer’s Comirnaty: Study

Medical Marketing and Media

Moderna Therapeutics

Flag link:

Pfizer tops pharma reputation rankings from autoimmune patients

Pfizer tops pharma reputation rankings from autoimmune patients

Medical Marketing and Media

autoimmune disease

Flag link:

Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma

Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma

Drugs.com

breakthrough therapy

relapsed or refractory multiple myeloma

Flag link:

Pfizer, BioNTech start COVID-flu combination vaccine study

Pfizer, BioNTech start COVID-flu combination vaccine study

Reuters

clinical trials

Flag link:

With FDA decision penciled in for May, GSK powers ahead in RSV race with Pfizer

With FDA decision penciled in for May, GSK powers ahead in RSV race with Pfizer

Fierce Biotech

Flag link:

FDA chief stands by Paxlovid nod amid discussion on 'rebound' cases

FDA chief stands by Paxlovid nod amid discussion on 'rebound' cases

Fierce Pharma

Flag link:

After promising trial results for maternal RSV vaccine, Pfizer says it will seek FDA approval this year

After promising trial results for maternal RSV vaccine, Pfizer says it will seek FDA approval this year

CNN

maternal vaccines

clinical trials

Flag link:

Pfizer discards eczema, NASH and breast cancer programs in early-phase clean-out

Pfizer discards eczema, NASH and breast cancer programs in early-phase clean-out

Fierce Biotech

Flag link:

Eli Lilly revenue inches up 2%, Pfizer raises full year outlook

Eli Lilly revenue inches up 2%, Pfizer raises full year outlook

Medical Marketing and Media

Flag link:

Pfizer under Italian finance probe over alleged $1.2B profits offshoring

Pfizer under Italian finance probe over alleged $1.2B profits offshoring

Fierce Pharma

Flag link:

After going head-to-head with Prevnar 20, Vaxcyte's 24-valent pneumococcal shot will seek a pivotal win

After going head-to-head with Prevnar 20, Vaxcyte's 24-valent pneumococcal shot will seek a pivotal win

Endpoints

pneumococcal disease

clinical trials

Flag link:

Pfizer blueprints €1B site in Ireland as industry's local investment spree rolls on: report

Pfizer blueprints €1B site in Ireland as industry's local investment spree rolls on: report

Fierce Pharma

drug manufacturing

Flag link:

As government funding dries up, Pfizer expects to charge private payers $110+ for Covid-19 vaccine

As government funding dries up, Pfizer expects to charge private payers $110+ for Covid-19 vaccine

Endpoints

Flag link:

Pfizer and Erasca Target Pancreatic, Colorectal Cancer with "Synergistic" Pairing

Pfizer and Erasca Target Pancreatic, Colorectal Cancer with "Synergistic" Pairing

BioSpace

colorectal cancer

Flag link:

Pfizer CEO Bourla says company ready to execute in a 'pivotal' 2023: report

Pfizer CEO Bourla says company ready to execute in a 'pivotal' 2023: report

Fierce Pharma

Flag link:

Pages